Trial Profile

COG Erwinase Use for Acute Lymphoblastic Leukemia (ALL) Treatment Under IND 290.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Crisantaspase (Primary)
Indications B-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
Focus Adverse reactions; Expanded access; Therapeutic Use
Acronyms EMTP

Most Recent Events

09 Jun 2010 New source identified and integrated (Vanderbilt-Ingram Cancer Center, VICCPED0711).
21 Apr 2009 New source identified and integrated (Barbara Ann Karmanos Cancer Institute).
21 Apr 2009 Additional lead trial investigator identified as reported by Barbara Ann Karmanos Cancer Institute.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com